CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of the literature.

A case of cryoglobulinemia type II with membranoproliferative glomerulonephritis and vasculitis is described. Clinically and serologically the patient responded to cyclophosphamide and prednisone therapy. This correlated with improvement in the glomerular and interstitial lesions on renal biopsy specimens, although skin and renal vasculitis persisted over a 2-year period. These observations suggest important differences in the immunopathologic mechanisms involved in the vascular versus glomerular injury. Infiltration of macrophages were demonstrated in the glomerular capillary lumen while polymorphonuclear cells predominated in the vascular lesion. The presence of macrophages in the glomerular capillary lumen correlated with clinical proteinuria. A review of the literature also suggests that cyclophosphamide in combination with prednisone appears to be an effective therapeutic regimen for the glomerulonephritis of cryoglobulinemia. However, the correlation of clinical response and renal morphology in cryoglobulinemia has heretofore not been emphasized.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app